Leukaemia UK

We’re delighted to announce that, together with @LymphomaAction, @MyelomaUK and @NHSEngland, we’re developing and implementing the first ever national framework to improve diagnosis, treatment and care for people affected by blood cancers. 🩸 Read more: leukaemiauk.org.uk/news/the-first…

Could a breath test detect blood cancer? Groundbreaking research from @QMUL found unique chemical signatures in the breaths of blood cancer patients, pointing to disease-specific molecular changes. A potential game-changer for earlier diagnosis. 🤞 qmul.ac.uk/media/news/202…

Huge thanks to Ed Argar MP for supporting our work to save and improve the lives of those affected by leukaemia. We wish him a speedy recovery and look forward to continuing to work with him in his capacity as MP.

Researchers may have cracked CAR-T therapy for T-cell ALL – an aggressive leukaemia with few options for adults. Using two protein targets (CD1a + CCR9), the team @Menendez_Lab developed a dual CAR-T that fights cancer without killing healthy T-cells. 👏 ecancer.org/en/news/26706-…

Congratulations to our former John Goldman Fellow @MariaTeresaEs on being awarded a research grant to lead vital work into new therapeutic interventions for children with acute myeloid leukaemia (AML). We look forward to seeing the outcome of this vital research. 👏

We welcome the publication of the 10 Year Health Plan, particularly the commitment to improving cancer outcomes. We're pleased to see the universal rollout of cancer genomics - something we have long advocated for & is essential to drive the best outcomes for leukaemia patients.

Early signs often seem harmless - but knowing the common symptoms of leukaemia can be lifesaving. 🩸 Brendan’s ‘flu-like’ symptoms turned out to be acute myeloid leukaemia (AML) - one of the most aggressive types of blood cancer. expressandstar.com/news/2025/06/2…

From targeting a new marker in AML to uncovering the immune system’s role in MPNs and finding a gentler combo for childhood leukaemia - our funded researchers have been busy! 🧪👏 Here are just a few publication highlights 👉 leukaemiauk.org.uk/stories/resear…

We’re proud to be one of the charities collaborating with @AMRC to support groundbreaking medical research across the UK. It’s inspiring to see the collective impact of AMRC member charities - investing in universities, the NHS, and nurturing the next generation of R&D talent.

We were pleased to co-host an event in Northern Ireland with @LeukaemiaCareUK this week, bringing together clinical and policy experts to discuss how we can work together to drive improvements for leukaemia patients. @healthdpt

We attended #EHA2025 where major advances in #leukaemia were shared. 🔬 Menin inhibitors show promise in AML 👴 Age shouldn't limit treatment options 🏠 Push for oral, at-home therapies 🧬 T-ALL: 15 subtypes ID’d for personalised care #BloodCancer #AML #Haematology

We’ve been hearing from @wesstreeting and @NHSEngland's Sir Jim Mackey on updates for @DHSCgovuk’s 10 Year Health Plan. We will continue working to ensure that improvements for leukaemia are included in the political agenda.

Huge congrats to our John Goldman Fellow, Dr Simon Mitchell @SiFTW, on the one-year anniversary of the Sussex Cancer Research Centre (SCRC) - an ambitious, collaborative hub supporting new PhD students, pioneering research projects and driving interdisciplinary collaborations. 🎉

Leukaemia patients need clinical trials for treatment—but opportunities have dropped since COVID, and access is still unequal. Today's plan to integrate trial access into the NHS app is a vital step toward faster, fairer access to life-saving research. bit.ly/43KFn21

Great news from the UK-led FLAIR trial! A chemo-free combo (ibrutinib + venetoclax) shows significantly better 5-year outcomes for CLL— 94% of patients alive & progression-free. A big step toward kinder, more effective treatments. ow.ly/WFEy50W9Tj9

Fantastic to hear that more innovative therapies are being approved for blood cancer patients, leading to better outcomes. 🧡 We hope to see more treatments like this becoming available for leukaemia patients.

We welcome the Government’s investment in R&D and the NHS in today’s #SpendingReview. We will continue pushing for bold commitments through the Rare Cancers Bill and the upcoming 10-Year Cancer Plan - to drive improvements in leukaemia research, diagnosis, treatment and care.

Exciting news from @GiuliaOrlandoGO and collaborators! Their new paper identifies a biomarker for poor prognosis in BP-MPN, opening the door to new, targeted treatments and understanding resistance. 👏